MYCN and neuroblastoma: We previously found that MYCN was not amplified in 74% of the 341 tumors for which the data passed quality control.[20] Analysis of the SNP dataset revealed that the PRKCQ‐AS1 was deleted in 5 and gained in 5 of the MYCN‐nonamplified human neuroblastoma tumors (Table S1, Supporting Information), suggesting that PRKCQ‐AS1 copy number variation is uncommon in neuroblastoma.